针对TDP-43的抗体减轻了ALS脑脊液诱导的致病途径
Amélie Poulin-Brière1, Silvia Pozzi2, Jean-Pierre Julien2
1CERVO Brain Research Center 2601 Chemin de la Canardière, Québec, QC G1J 2G3, Canada.
概括
一种针对 TAR DNA 结合蛋白 43 (TDP-43) 的 RRM1 域的新型免疫疗法显示为治疗肌缩性侧面硬化症 (ALS) 的前景. 在ALS小鼠模型中,E6抗体减少了疾病症状和神经退行.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病,与TDP-43错位化有关.
- 以前的研究表明,针对TDP-43的RRM1域的单克隆抗体 (E6) 在突变的TDP-43小鼠中具有保护性.
研究的目的:
- 用患者脑脊液 (CSF) 来评估E6抗体在偶发性ALS小鼠模型中的治疗潜力.
- 研究E6抗体对运动和认知功能的影响,TDP-43蛋白质病变,神经炎症和神经元完整性的研究.
主要方法:
- 转基因小鼠表达野生型TDP-43 (TDP-43WT) 被输入零星ALS患者的CSF.
- E6抗体是通过内 (i.t.) 进行的. 或是通过脑内脑室内 (ICV) 输入. ) 的情况.
- 评估了运动和认知表现,TDP-43病理,神经丝组织,运动神经元损失,神经肌肉结节化和微质激活.
主要成果:
- 在ALS小鼠模型中,E6抗体治疗显著减少了运动和认知缺陷.
- 该抗体减轻了TDP-43蛋白质病变,防止了神经纤维的失调,并减少了运动神经元损失和神经肌肉结节缩.
- 服用E6促进了微质激活向保护性,细胞表型的转变,减少了促炎性细胞因子分泌.
结论:
- 针对TDP-43的RRM1域的免疫疗法显示出对偶发ALS患者CSF诱导的致病机制的保护作用.
- 该E6抗体通过解决TDP-43蛋白病变和神经炎症,代表了ALS的潜在治疗策略.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K


